Razuprotafib is a selective glucagon-like peptide-1 receptor agonist classified as an incretin mimetic, developed to improve glycemic control and lower cardiovascular risk in patients with type 2 diabetes… Read more
Razuprotafib is a selective glucagon-like peptide-1 receptor agonist classified as an incretin mimetic, developed to improve glycemic control and lower cardiovascular risk in patients with type 2 diabetes mellitus. This category provides access to high-quality reference standards essential for pharmaceutical research and rigorous analytical testing. By offering the parent compound alongside stable isotope labelled compounds such as Razuprotafib-d5 and related analogues, these products support precise mass spectrometry-based quantification in bioanalytical assays. Laboratories utilize these materials for validating pharmacokinetic studies and conducting comprehensive impurity profiling of the active pharmaceutical ingredient. These reference standards ensure that analytical methods maintain the high level of accuracy required for quality control and regulatory compliance throughout the drug development lifecycle.